FMC Corporation delivered a paradoxical start to the year: stronger-than-expected operational performance overshadowed by a steep financial loss, as the company doubled down on its full-year forecast and signalled ongoing strategic maneuvering.

 

The crop protection giant posted first-quarter revenue of $759 million, down 4 percent year-on-year, while adjusted EBITDA landed at $72 million—beating the high end of guidance but still plunging 40 percent from 2025 levels.

 

The headline shock came from the bottom line: a GAAP net loss of $281 million, a $266 million deterioration from a year ago, driven largely by tax-related charges, restructuring costs, and rising interest expenses.

 

Despite the hit, FMC struck a confident tone.

 

Sales excluding its India business edged above expectations, buoyed by growth in North America and EMEA, where volumes rose and new product sales surged. Revenue from new active ingredients doubled compared to last year, offering a rare bright spot amid pricing pressure and weaker legacy product demand—particularly in Latin America.

 

Still, pricing cuts—especially tied to its flagship Rynaxypyr® portfolio and competitive market conditions—dragged overall performance, while tariffs and raw material costs squeezed margins.

 

Cash flow painted an even bleaker picture. Operating cash flow sank to negative $601 million, pushing free cash flow to negative $628 million for the quarter.

 

Yet FMC is holding its ground.

 

The company reaffirmed its full-year 2026 outlook, projecting revenue between $3.60 billion and $3.80 billion and adjusted EBITDA of $670 million to $730 million. Earnings per share are expected to fall sharply, down 41 percent at the midpoint, reflecting continued pricing pressure and higher financing costs.

 

Behind the scenes, FMC is pursuing a dual-track strategy: cutting roughly $1 billion in debt while exploring strategic alternatives, a process launched earlier this year that could reshape the company’s future.

 

For now, leadership is staying tight-lipped on that review, emphasizing that “multiple options are being evaluated” without guaranteeing any deal.

 

Looking ahead, the second quarter is expected to bring further strain, with revenue forecast to drop as much as 17 percent and earnings falling even more sharply, hit by lower volumes and the absence of its India business.

 

The bigger bet lies in the back half of the year. FMC is counting on volume growth—driven by new chemistry and product innovation—to offset pricing headwinds and stabilize performance.

 

Whether that rebound materializes will determine if this quarter’s mixed signals mark a temporary dip—or a deeper shift in the company’s trajectory.